Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Anorexia Nervosa Therapeutics - Pipeline Assessment and Market Forecasts to 2018Anorexia Nervosa Therapeutics Market to Show Steady Growth until 2018
By: Rajesh Gunnam 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 8.9% to $25m by 2018. The future market is set to witness steady growth until 2018, primarily attributed to an increasing patient pool and public awareness of the disorder. Molecule SUN11031 (human ghrelin hormone) from Daiichi Sankyo is expected to be launched in Japan in 2014 but is not expected to be a significant driver for the anorexia therapeutics market. A low treatment rate, the high cost of therapy, non - supportive government reimbursement policies and non - availability of an approved therapy able to completely cure anorexia will act as barriers to market growth. GlobalData has found that the anorexia nervosa therapeutics has high unmet need as there is currently no approved therapy for the treatment of this disorder. This implies that there is scope for the launch of new products able to capture the anorexia nervosa therapeutics market. The current therapeutic landscape comprises off - label medications that treat only co - morbid conditions such as depression, anxiety, Obsessive Compulsive Disorder (OCD). The off - label medications include antidepressants (fluoxetine, clomipramine) GlobalData’s analysis indicates that there will be not a significant change to the future landscape of the anorexia nervosa therapeutics market, mainly attributed to the weak pipeline with only one first - in – class molecule (SUN11031) in the late stage of development. The present competition in the market is weak, as there is no approved therapy for treating the disorder. The present market is mainly dominated by the usage of off - label classes of drugs such as antidepressants, antipsychotics, anxiolytics and antihistamines. These drugs treat co - morbid conditions associated with anorexia such as depression, anxiety and OCD. SUN11031 is expected to be launched only in Japan in the forecast period and so will not impact the already weak competition. For Sample Pages, please click or add the below link to your browser: http://globaldata.com/ GlobalData analysis shows that the anorexia nervosa therapeutics pipeline is weak with only five molecules in various Phases of development. SUN11031 is the only first - in - class molecule in the late stage of development and it is expected to be launched in Japan in the forecast period. The late stage pipeline has only one molecule with a novel mechanism of action and the other two are generics. Therefore, it is expected that the launch of SUN11031 will not significantly contribute to the growth of the market, leading to steady market growth GlobalData, the industry analysis specialist, has released its new report, “Anorexia Nervosa Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global therapeutics market, identifying the key trends shaping and driving the global anorexia nervosa therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, it provides valuable insights on the pipeline products within the global anorexia nervosa therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number